PDCD1 and neoplasm: In contrast, PD-1 mainly operates during the effector phase in peripheral tissues, where its ligand PD-L1–widely expressed on tumor cells and interferon-γ-stimulated immune cells—transmits inhibitory signals that lead to T-cell exhaustion, reduced cytokine production, and weakened antitumor activity (11–13).